Ardelyx Stock Price, News & Analysis (NASDAQ:ARDX)

$5.70 0.10 (1.79 %)
(As of 11/20/2017 02:37 AM ET)
Previous Close$5.60
Today's Range$5.55 - $5.75
52-Week Range$4.05 - $16.30
Volume217,200 shs
Average Volume500,935 shs
Market Capitalization$270.95 million
P/E RatioN/A
Dividend YieldN/A
Beta0.19

About Ardelyx (NASDAQ:ARDX)

Ardelyx logoArdelyx, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company's products line includes cardiorenal portfolio and gastrointestinal portfolio. The Company's cardiorenal portfolio includes two Phase III clinical product candidates, tenapanor in Phase III clinical development for treating hyperphosphatemia in end-stage renal disease (ESRD) patients on dialysis and RDX7675 in Phase III clinical development for treating hyperkalemia in chronic kidney disease (CKD) and heart failure patients. The cardiorenal portfolio includes tenapanor, RDX7675, RDX013 and RDX011. Its gastrointestinal portfolio is led by tenapanor for the treatment of irritable bowel syndrome with constipation (IBS-C). The gastrointestinal portfolio includes tenapanor, RDX8940, RDX011 and RDX023.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: NASDAQ:ARDX
  • CUSIP: N/A
  • Web: www.ardelyx.com
Debt:
  • Current Ratio: 8.50%
  • Quick Ratio: 8.50%
Sales & Book Value:
  • Annual Sales: $24.03 million
  • Price / Sales: 11.27
  • Book Value: $4.08 per share
  • Price / Book: 1.40
Profitability:
  • Trailing EPS: ($2.23)
  • Net Income: ($112,380,000.00)
  • Return on Equity: -66.87%
  • Return on Assets: -59.72%
Misc:
  • Employees: 93
  • Outstanding Shares: 47,530,000
 

Frequently Asked Questions for Ardelyx (NASDAQ:ARDX)

What is Ardelyx's stock symbol?

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

How were Ardelyx's earnings last quarter?

Ardelyx, Inc. (NASDAQ:ARDX) posted its quarterly earnings data on Tuesday, November, 7th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.54) by $0.10. During the same period last year, the firm posted ($0.65) earnings per share. View Ardelyx's Earnings History.

Where is Ardelyx's stock going? Where will Ardelyx's stock price be in 2017?

5 analysts have issued 1 year price objectives for Ardelyx's stock. Their predictions range from $12.00 to $24.00. On average, they expect Ardelyx's share price to reach $16.40 in the next twelve months. View Analyst Ratings for Ardelyx.

What are Wall Street analysts saying about Ardelyx stock?

Here are some recent quotes from research analysts about Ardelyx stock:

  • 1. According to Zacks Investment Research, "Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases. The Company's lead product candidate is Tenapanor which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. Ardelyx, Inc. is headquartered in Fremont, California. " (11/10/2017)
  • 2. Cantor Fitzgerald analysts commented, "T3MPO-1 is a Relevant Trial. The results of the trial, disclosed May 12, yielded a statistically significant outcome in the primary endpoint and in seven of eight secondary endpoints. However, the results showed a less-than-expected benefit, in our view, with 27% of tenapanor-treated patients achieving the primary endpoint versus 18.7% for placebo (p=0.02), although the responder rate was less than was observed in the Phase IIb study." (5/31/2017)

Are investors shorting Ardelyx?

Ardelyx saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 1,812,355 shares, an increase of 48.0% from the October 13th total of 1,224,464 shares. Based on an average trading volume of 1,054,159 shares, the short-interest ratio is currently 1.7 days. Currently, 6.1% of the company's stock are sold short.

Who are some of Ardelyx's key competitors?

Who are Ardelyx's key executives?

Ardelyx's management team includes the folowing people:

  • David M. Mott, Independent Chairman of the Board (Age 51)
  • Michael G. Raab, President, Chief Executive Officer, Director (Age 52)
  • Mark E. Kaufmann, Chief Financial Officer, Principal Accounting Officer (Age 49)
  • Reginal Seeto, Chief Operating Officer, Executive Vice President (Age 45)
  • Jeremy S. Caldwell Ph.D., Executive Vice President, Chief Scientific Officer (Age 48)
  • Elizabeth Grammer Esq., Senior Vice President, General Counsel (Age 53)
  • David P. Rosenbaum Ph.D., Chief Development Officer (Age 56)
  • Robert B. Bazemore Jr., Independent Director (Age 49)
  • William C. Bertrand Jr. Esq., Independent Director (Age 52)
  • Annalisa M. Jenkins, Independent Director (Age 52)

Who owns Ardelyx stock?

Ardelyx's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FLYNN JAMES E (5.79%), ROCK SPRINGS CAPITAL MANAGEMENT LP (5.02%), Perceptive Advisors LLC (2.85%), First Manhattan Co. (1.23%), Dimensional Fund Advisors LP (0.90%) and Axiom International Investors LLC DE (0.39%). Company insiders that own Ardelyx stock include David P Rosenbaum, Elizabeth A Grammer, Forest Baskett, Gordon Ringold, Jeffrey W Jacobs, Jeremy S Caldwell, Nea 15 Gp, Llc and Reginald Seeto. View Institutional Ownership Trends for Ardelyx.

Who sold Ardelyx stock? Who is selling Ardelyx stock?

Ardelyx's stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Crestline Management LP, First Manhattan Co. and Trexquant Investment LP. Company insiders that have sold Ardelyx company stock in the last year include David P Rosenbaum, Forest Baskett, Jeremy S Caldwell and Reginald Seeto. View Insider Buying and Selling for Ardelyx.

Who bought Ardelyx stock? Who is buying Ardelyx stock?

Ardelyx's stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Axiom International Investors LLC DE, IndexIQ Advisors LLC, Sei Investments Co. and Citadel Advisors LLC. Company insiders that have bought Ardelyx stock in the last two years include Gordon Ringold and Nea 15 Gp, Llc. View Insider Buying and Selling for Ardelyx.

How do I buy Ardelyx stock?

Shares of Ardelyx can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ardelyx's stock price today?

One share of Ardelyx stock can currently be purchased for approximately $5.70.

How big of a company is Ardelyx?

Ardelyx has a market capitalization of $270.95 million and generates $24.03 million in revenue each year. The biopharmaceutical company earns ($112,380,000.00) in net income (profit) each year or ($2.23) on an earnings per share basis. Ardelyx employs 93 workers across the globe.

How can I contact Ardelyx?

Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company can be reached via phone at 510-745-1700 or via email at [email protected]


MarketBeat Community Rating for Ardelyx (NASDAQ ARDX)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  185 (Vote Outperform)
Underperform Votes:  105 (Vote Underperform)
Total Votes:  290
MarketBeat's community ratings are surveys of what our community members think about Ardelyx and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Ardelyx (NASDAQ:ARDX)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 5 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $16.40 (187.72% upside)

Consensus Price Target History for Ardelyx (NASDAQ:ARDX)

Price Target History for Ardelyx (NASDAQ:ARDX)

Analysts' Ratings History for Ardelyx (NASDAQ:ARDX)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/17/2017Leerink SwannReiterated RatingOutperform$13.00N/AView Rating Details
10/12/2017Citigroup Inc.Boost Price TargetBuy$14.00 -> $19.00N/AView Rating Details
10/12/2017Cantor FitzgeraldBoost Price TargetOverweight$12.00 -> $14.00N/AView Rating Details
5/23/2017BTIG ResearchLower Price TargetBuy$18.00 -> $12.00HighView Rating Details
2/15/2017WedbushReiterated RatingOutperform$24.00N/AView Rating Details
3/31/2016Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$21.00N/AView Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$26.00 -> $21.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$26.00 -> $21.00N/AView Rating Details
(Data available from 11/20/2015 forward)

Earnings

Earnings History and Estimates Chart for Ardelyx (NASDAQ:ARDX)

Earnings by Quarter for Ardelyx (NASDAQ:ARDX)

Earnings History by Quarter for Ardelyx (NASDAQ ARDX)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($0.54)($0.44)ViewN/AView Earnings Details
8/9/2017Q2 2017($0.63)($0.54)ViewListenView Earnings Details
5/5/2017Q1 2017($0.65)($0.59)ViewN/AView Earnings Details
2/17/2017Q4 2016($0.66)($0.66)ViewN/AView Earnings Details
11/7/2016Q316($0.74)($0.65)ViewListenView Earnings Details
8/8/2016Q216($0.75)($0.83)ViewN/AView Earnings Details
5/9/2016Q116($0.66)($0.70)ViewN/AView Earnings Details
3/4/2016Q4($0.82)($0.65)ViewN/AView Earnings Details
11/12/2015Q315($0.48)($0.70)ViewListenView Earnings Details
8/12/2015Q215$0.09$0.42$25.87 million$17.70 millionViewListenView Earnings Details
5/12/2015Q1($0.02)($0.19)$9.65 million$5.88 millionViewN/AView Earnings Details
2/25/2015Q4 2014($0.06)($0.21)$8.15 million$6.34 millionViewListenView Earnings Details
8/7/2014Q2 2014$1.83$0.44$8.10 million$9.14 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ardelyx (NASDAQ:ARDX)
2017 EPS Consensus Estimate: ($2.25)
2018 EPS Consensus Estimate: ($1.76)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.65)($0.65)($0.65)
Q2 20171($0.63)($0.63)($0.63)
Q3 20172($0.56)($0.48)($0.52)
Q4 20172($0.46)($0.44)($0.45)
Q1 20181($0.42)($0.42)($0.42)
Q2 20181($0.45)($0.45)($0.45)
Q3 20181($0.47)($0.47)($0.47)
Q4 20181($0.42)($0.42)($0.42)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ardelyx (NASDAQ:ARDX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Ardelyx (NASDAQ ARDX)

Insider Ownership Percentage: 15.47%
Institutional Ownership Percentage: 78.82%
Insider Trades by Quarter for Ardelyx (NASDAQ:ARDX)
Institutional Ownership by Quarter for Ardelyx (NASDAQ:ARDX)

Insider Trades by Quarter for Ardelyx (NASDAQ ARDX)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/24/2017Reginald SeetoCOOSell10,008$5.20$52,041.60View SEC Filing  
8/30/2017Forest BaskettMajor ShareholderSell485$4.95$2,400.75View SEC Filing  
4/18/2017David P. RosenbaumInsiderSell2,051$11.98$24,570.98View SEC Filing  
3/3/2017Jeremy S. CaldwellEVPSell1,026$14.14$14,507.64View SEC Filing  
12/16/2016David P RosenbaumSVPSell900$14.48$13,032.00View SEC Filing  
10/11/2016Jeffrey W. JacobsSVPSell6,000$15.00$90,000.00View SEC Filing  
9/23/2016Elizabeth A GrammerSVPSell5,000$12.00$60,000.00View SEC Filing  
9/19/2016Elizabeth A. GrammerSVPSell6,859$11.21$76,889.39View SEC Filing  
7/18/2016Nea 15 Gp, LlcMajor ShareholderBuy1,527,301$8.73$13,333,337.73View SEC Filing  
3/21/2016Gordon RingoldDirectorBuy15,000$7.77$116,550.00View SEC Filing  
1/13/2016Nea 15 Gp, LlcMajor ShareholderBuy1,000,000$10.00$10,000,000.00View SEC Filing  
11/27/2015Jeffrey W. JacobsSVPSell2,000$20.00$40,000.00View SEC Filing  
10/8/2015Jeffrey W. JacobsSVPSell2,000$19.88$39,760.00View SEC Filing  
9/22/2015David P. RosenbaumSVPSell1,400$22.05$30,870.00View SEC Filing  
9/15/2015David P RosenbaumSVPSell2,540$22.01$55,905.40View SEC Filing  
9/10/2015Jeffrey W. JacobsSVPSell2,000$20.59$41,180.00View SEC Filing  
9/8/2015Michael RaabCEOSell9,785$20.29$198,537.65View SEC Filing  
9/3/2015David P RosenbaumSVPSell2,537$18.78$47,644.86View SEC Filing  
7/22/2015Elizabeth A GrammerVPSell2,500$18.00$45,000.00View SEC Filing  
7/15/2015Elizabeth A GrammerVPSell10,000$17.12$171,200.00View SEC Filing  
6/10/2015Gordon RingoldDirectorBuy10,000$15.19$151,900.00View SEC Filing  
6/5/2015Enterprise Associates 12 NewMajor ShareholderBuy1,869,159$10.70$20,000,001.30View SEC Filing  
6/5/2015Peter G SchultzDirectorBuy46,729$10.70$500,000.30View SEC Filing  
5/4/2015Mark KaufmannCFOSell9,083$10.81$98,187.23View SEC Filing  
4/6/2015Mark KaufmannCFOSell7,681$12.80$98,316.80View SEC Filing  
3/2/2015Elizabeth A GrammerVPSell1,737$15.81$27,461.97View SEC Filing  
2/4/2015Jeffrey W JacobsVPSell8,888$16.28$144,696.64View SEC Filing  
1/8/2015Ventures Vii Lp CmeaMajor ShareholderSell300,000$24.25$7,275,000.00View SEC Filing  
12/26/2014Scott D SandellMajor ShareholderSell1,972$21.28$41,964.16View SEC Filing  
6/24/2014Ventures Vii Lp CmeaMajor ShareholderBuy316,826$14.00$4,435,564.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Ardelyx (NASDAQ ARDX)

Source:
DateHeadline
Stock Performance Review on Biotech Industry -- Ardelyx, Bellicum Pharma, Iovance Biotherapeutics, and Inotek PharmaStock Performance Review on Biotech Industry -- Ardelyx, Bellicum Pharma, Iovance Biotherapeutics, and Inotek Pharma
www.bizjournals.com - November 16 at 4:15 PM
Stock Performance Review on Biotech Industry -- Ardelyx, Bellicum Pharma, Iovance Biotherapeutics, and Inotek Pharma - PR Newswire (press release)Stock Performance Review on Biotech Industry -- Ardelyx, Bellicum Pharma, Iovance Biotherapeutics, and Inotek Pharma - PR Newswire (press release)
www.prnewswire.com - November 16 at 11:26 AM
Ardelyx, Inc. (ARDX) Receives Consensus Rating of "Buy" from AnalystsArdelyx, Inc. (ARDX) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - November 16 at 9:08 AM
Ardelyx, Inc. (ARDX) Short Interest UpdateArdelyx, Inc. (ARDX) Short Interest Update
www.americanbankingnews.com - November 13 at 2:32 AM
Ardelyx, Inc. (ARDX) Upgraded to "Buy" at Zacks Investment ResearchArdelyx, Inc. (ARDX) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - November 11 at 8:58 PM
FY2017 Earnings Estimate for Ardelyx, Inc. Issued By Wedbush (ARDX)FY2017 Earnings Estimate for Ardelyx, Inc. Issued By Wedbush (ARDX)
www.americanbankingnews.com - November 10 at 8:34 AM
Ardelyx, Inc. to Post FY2017 Earnings of ($2.03) Per Share, Leerink Swann Forecasts (ARDX)Ardelyx, Inc. to Post FY2017 Earnings of ($2.03) Per Share, Leerink Swann Forecasts (ARDX)
www.americanbankingnews.com - November 9 at 8:31 AM
Ardelyx, Inc. (ARDX) Issues  Earnings Results, Beats Estimates By $0.10 EPSArdelyx, Inc. (ARDX) Issues Earnings Results, Beats Estimates By $0.10 EPS
www.americanbankingnews.com - November 8 at 4:23 PM
Ardelyx Reports Third Quarter 2017 Operating Results and Clinical ProgressArdelyx Reports Third Quarter 2017 Operating Results and Clinical Progress
finance.yahoo.com - November 7 at 5:46 PM
Ardelyx reports 3Q lossArdelyx reports 3Q loss
finance.yahoo.com - November 7 at 5:46 PM
Zacks: Brokerages Anticipate Ardelyx, Inc. (ARDX) to Post -$0.52 Earnings Per ShareZacks: Brokerages Anticipate Ardelyx, Inc. (ARDX) to Post -$0.52 Earnings Per Share
www.americanbankingnews.com - November 5 at 11:44 AM
Growth Stocks Investors LoveGrowth Stocks Investors Love
finance.yahoo.com - October 31 at 5:14 PM
Ardelyx, Inc. (ARDX) to Release Earnings on MondayArdelyx, Inc. (ARDX) to Release Earnings on Monday
www.americanbankingnews.com - October 30 at 8:50 AM
Ardelyx, Inc. (ARDX) COO Sells $52,041.60 in StockArdelyx, Inc. (ARDX) COO Sells $52,041.60 in Stock
www.americanbankingnews.com - October 26 at 8:58 PM
Ardelyx, Inc. (ARDX) Receives Average Rating of "Hold" from AnalystsArdelyx, Inc. (ARDX) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - October 22 at 8:52 AM
Ardelyx, Inc. to Post Q3 2017 Earnings of ($0.48) Per Share, Leerink Swann Forecasts (ARDX)Ardelyx, Inc. to Post Q3 2017 Earnings of ($0.48) Per Share, Leerink Swann Forecasts (ARDX)
www.americanbankingnews.com - October 19 at 7:58 AM
H.C. Wainwright Pounds the Table on Synergy Pharmaceuticals Inc (SGYP)H.C. Wainwright Pounds the Table on Synergy Pharmaceuticals Inc (SGYP)
finance.yahoo.com - October 18 at 5:17 PM
Ardelyx (ARDX) Reports Data from Pre-Clinical Studies that Tenapanor Reduces Pain Caused by IBS-C Through ... - StreetInsider.comArdelyx (ARDX) Reports Data from Pre-Clinical Studies that Tenapanor Reduces Pain Caused by IBS-C Through ... - StreetInsider.com
www.streetinsider.com - October 17 at 9:58 PM
UPDATE: Leerink Partners Resumes Ardelyx, Inc (ARDX) at Outperform - StreetInsider.comUPDATE: Leerink Partners Resumes Ardelyx, Inc (ARDX) at Outperform - StreetInsider.com
www.streetinsider.com - October 17 at 9:58 PM
Ardelyx, Inc. (ARDX) Downgraded by Zacks Investment Research to "Sell"Ardelyx, Inc. (ARDX) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - October 17 at 5:50 PM
Ardelyx, Inc. (ARDX) Research Coverage Started at Leerink SwannArdelyx, Inc. (ARDX) Research Coverage Started at Leerink Swann
www.americanbankingnews.com - October 17 at 8:30 AM
Zacks: Brokerages Expect Ardelyx, Inc. (ARDX) to Announce -$0.56 Earnings Per ShareZacks: Brokerages Expect Ardelyx, Inc. (ARDX) to Announce -$0.56 Earnings Per Share
www.americanbankingnews.com - October 16 at 10:30 PM
Ardelyx Announces Tenapanor Reduces Pain Caused by IBS-C Through Inhibition of TRPV-1 SignalingArdelyx Announces Tenapanor Reduces Pain Caused by IBS-C Through Inhibition of TRPV-1 Signaling
finance.yahoo.com - October 16 at 4:51 PM
FY2017 EPS Estimates for Ardelyx, Inc. Decreased by Wedbush (ARDX)FY2017 EPS Estimates for Ardelyx, Inc. Decreased by Wedbush (ARDX)
www.americanbankingnews.com - October 16 at 4:52 AM
Cantor Fitzgerald Boosts Ardelyx, Inc. (ARDX) Price Target to $14.00Cantor Fitzgerald Boosts Ardelyx, Inc. (ARDX) Price Target to $14.00
www.americanbankingnews.com - October 14 at 7:38 PM
Ardelyx, Inc (ARDX) PT Raised to $15 at BTIG - StreetInsider.comArdelyx, Inc (ARDX) PT Raised to $15 at BTIG - StreetInsider.com
www.streetinsider.com - October 13 at 2:55 AM
Ardelyx, Inc (ARDX) PT Raised to $16 at Wedbush; Tenapanor Approval in IBS-C Almost Certain - StreetInsider.comArdelyx, Inc (ARDX) PT Raised to $16 at Wedbush; Tenapanor Approval in IBS-C 'Almost Certain' - StreetInsider.com
www.streetinsider.com - October 13 at 2:55 AM
Ardelyx jumps more than 60% after positive study results - MarketWatchArdelyx jumps more than 60% after positive study results - MarketWatch
www.marketwatch.com - October 13 at 2:55 AM
Why Ardelyx Inc Skyrocketed Higher TodayWhy Ardelyx Inc Skyrocketed Higher Today
finance.yahoo.com - October 12 at 9:52 PM
Ardelyx (ARDX) Says Phase 3 Study of Tenapanor for IBS-C Hit Primary and All Secondary EndpointsArdelyx (ARDX) Says Phase 3 Study of Tenapanor for IBS-C Hit Primary and All Secondary Endpoints
www.streetinsider.com - October 12 at 4:52 PM
Ardelyx Inc. (ARDX) Has Jumped To A 5-Month High On Phase 3 Study ResultsArdelyx Inc. (ARDX) Has Jumped To A 5-Month High On Phase 3 Study Results
www.rttnews.com - October 12 at 4:52 PM
Ardelyx Soars on Positive Phase 3 Data -- Biotech MoversArdelyx Soars on Positive Phase 3 Data -- Biotech Movers
finance.yahoo.com - October 12 at 4:52 PM
Why Spartan Motors, Ardelyx, and Glu Mobile Jumped TodayWhy Spartan Motors, Ardelyx, and Glu Mobile Jumped Today
finance.yahoo.com - October 12 at 4:52 PM
Citigroup Inc. Boosts Ardelyx, Inc. (ARDX) Price Target to $19.00Citigroup Inc. Boosts Ardelyx, Inc. (ARDX) Price Target to $19.00
www.americanbankingnews.com - October 12 at 12:40 PM
ARDX Surges After-hours, MBVX Abuzz, TRVN Keeps Its FocusARDX Surges After-hours, MBVX Abuzz, TRVN Keeps Its Focus
www.rttnews.com - October 12 at 3:36 AM
Ardelyx Inc. (ARDX) Is Climbing On Phase 3 Study ResultsArdelyx Inc. (ARDX) Is Climbing On Phase 3 Study Results
www.rttnews.com - October 11 at 5:32 PM
Ardelyxs Pivotal Phase 3 Study of Tenapanor for IBS-C Hits Primary and All Secondary Endpoints to Support NDA Submission in 2018Ardelyx's Pivotal Phase 3 Study of Tenapanor for IBS-C Hits Primary and All Secondary Endpoints to Support NDA Submission in 2018
finance.yahoo.com - October 11 at 5:32 PM
Ardelyxs irritable bowel syndrome drug succeeds in trialArdelyx's irritable bowel syndrome drug succeeds in trial
finance.yahoo.com - October 11 at 5:32 PM
Ardelyx jumps more than 60% after positive study resultsArdelyx jumps more than 60% after positive study results
finance.yahoo.com - October 11 at 5:32 PM
Cantor Fitzgerald Reiterates Buy Rating for Ardelyx, Inc. (ARDX)Cantor Fitzgerald Reiterates Buy Rating for Ardelyx, Inc. (ARDX)
www.americanbankingnews.com - October 11 at 5:20 PM
 Analysts Expect Ardelyx, Inc. (ARDX) to Announce -$0.56 Earnings Per Share Analysts Expect Ardelyx, Inc. (ARDX) to Announce -$0.56 Earnings Per Share
www.americanbankingnews.com - September 28 at 6:22 AM
Financial Analysis: Ardelyx (ARDX) and NeuroDerm (NDRM)Financial Analysis: Ardelyx (ARDX) and NeuroDerm (NDRM)
www.americanbankingnews.com - September 28 at 12:36 AM
Ardelyx, Inc. (ARDX) Receives Consensus Rating of "Buy" from BrokeragesArdelyx, Inc. (ARDX) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - September 27 at 8:56 AM
Financial Survey: Ardelyx (ARDX) versus The CompetitionFinancial Survey: Ardelyx (ARDX) versus The Competition
www.americanbankingnews.com - September 18 at 4:31 PM
 Brokerages Anticipate Ardelyx, Inc. (ARDX) to Announce -$0.56 Earnings Per Share Brokerages Anticipate Ardelyx, Inc. (ARDX) to Announce -$0.56 Earnings Per Share
www.americanbankingnews.com - September 9 at 10:22 AM
Ardelyx, Inc. (ARDX) Receives Average Recommendation of "Buy" from BrokeragesArdelyx, Inc. (ARDX) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - September 2 at 9:08 AM
Ardelyx, Inc. (ARDX) Earns Buy Rating from Cantor FitzgeraldArdelyx, Inc. (ARDX) Earns Buy Rating from Cantor Fitzgerald
www.americanbankingnews.com - August 28 at 10:16 AM
Equities Analysts Set Expectations for Ardelyx, Inc.s Q3 2017 Earnings (NASDAQ:ARDX)Equities Analysts Set Expectations for Ardelyx, Inc.'s Q3 2017 Earnings (NASDAQ:ARDX)
www.americanbankingnews.com - August 14 at 3:36 AM
Ardelyx, Inc. Forecasted to Post Q1 2018 Earnings of ($0.48) Per Share (NASDAQ:ARDX)Ardelyx, Inc. Forecasted to Post Q1 2018 Earnings of ($0.48) Per Share (NASDAQ:ARDX)
www.americanbankingnews.com - August 11 at 2:14 PM
Edited Transcript of ARDX earnings conference call or presentation 9-Aug-17 12:00pm GMTEdited Transcript of ARDX earnings conference call or presentation 9-Aug-17 12:00pm GMT
finance.yahoo.com - August 10 at 5:26 PM

Social Media

Financials

Chart

Ardelyx (NASDAQ ARDX) Chart for Monday, November, 20, 2017
Loading chart…

This page was last updated on 11/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.